Is this you?
Request access for Collaborative Neuroscience Research with your @cenexelresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Collaborative Neuroscience Research
Unclaimed profileSite Network · Garden Grove, California · ~4 sites
Intera lens
ICP 7Lift (cardio sample) 0.07Recruit soph 0.43
Quality Scorecard (1–100)
Overall74Recruit62Ops79Sponsor82Ther75
Performance (observed)
Historical trials
369
Completed
284
Terminated/Withdrawn
41
Completion rate
87%
Active now
39
Phase 2
135
Phase 3
152
Realized enrollment
279,278
First study year
2002
Years active
24
Match confidence
high
Enrollment velocity (inf)
11,637
Therapeutic
Areas
CNS (psychiatry, addiction, neurology, pain, ethnic bridging, vaccines)
Breadth (conditions)
210
Languages
English + Spanish (detected)
States
California
Recruitment (web observed)
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
Capability notes
High; part of CenExel network (600+ employees, $1.5B funding); 200+ years collective experience
Relationships
Sponsors
Pfizer; Sumitomo Pharma America, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; Eli Lilly and Company; Boehringer Ingelheim; AbbVie
CROs
ICON Clinical Research; Medpace, Inc.; PPD Development, LP; PRA Health Sciences; Syneos Health; Teva Branded Pharmaceutical Products R&D, Inc.
Owner / parent
Owned by CenExel Clinical Research (acquired June 2022, formerly Apex Innovative Sciences). CenExel founded 2018, $1.5B funding, headquartered Salt Lake City.
Capacity & people
Investigators
—
Coordinators
—
CEO
Sy Pretorius (CenExel parent)
VP Clinical Ops
Unknown
VP Site Ops
David Walling, MD (Chief Clinical Officer, prior owner/CEO)
VP Recruitment
Unknown
Emails
alamitors.info@CenExel.com
Tech & DCT
Builds tech
Unknown
Tech stack
Unknown
Recruiting visible
Y
Notes
Specialty CNS network acquired by CenExel (June 2022). Dr. David Walling (founder 2000, owned until 2022, now Chief Clinical Officer). Part of larger CenExel platform with 600+ employees. Phase I-IV complex CNS trials. Los Alamitos & Garden Grove hubs with satellite locations. CTGOV signal: 10 recruiting trials across 4 locations, California
Recommendation features (sample indication)
Ind fit 0.12Liftability 0.07Overall74
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.